(WO2016168634) 1. A method of treating a cancer, comprising administering to a patient diagnosed with said cancer a therapeutically effective amount of a HER3 inhibitor, an EGFR inhibitor, or a combination of a HER3 inhibitor and an EGFR inhibitor, wherein the patient has a tumor that has been characterized in that cells from the tumor: i) express a neuregulin, and ii) express high levels of one or more of amphiregulin (AREG), TGF-a, and EGFR homodimer. 57. A method of determining whether a patient diagnosed with cancer is indicated as likely to be responsive to treatment with a HER3 inhibitor, an EGFR inhibitor, or a combination of a HER3 inhibitor and an EGFR inhibitor, comprising measuring the expression of one or more of AREG, TGF-a, and EGFR homodimer in a sample from the patient, wherein the sample comprises tumor cells and a neuregulin, and wherein high levels of one or more of AREG, TGF-a, and EGFR homodimer in the sample indicates that the patient is likely to be responsive to treatment with a FIER3 inhibitor, an EGFR inhibitor, or a combination of a FIER3 inhibitor and an EGFR inhibitor. 58. A method of determining whether a patient diagnosed with cancer is indicated as likely to be responsive to treatment with a FIER3 inhibitor, an EGFR inhibitor, or a combination of a FIER3 inhibitor and an EGFR inhibitor, comprising measuring the expression of a neuregulin, and at least one of AREG, TGF-a, and EGFR homodimer in a sample from the patient, wherein the sample comprises tumor cells, and wherein the presence of the neuregulin and high levels of one or more of AREG, TGF-a, and EGFR homodimer in the sample indicates that the patient is likely to be responsive to treatment with a FIER3 inhibitor, an EGFR inhibitor, or a combination of a HER3 inhibitor and an EGFR inhibitor. 125. A method of treating a cancer, comprising administering to a patient diagnosed with said cancer a therapeutically effective amount of a HER3 inhibitor, an EGFR inhibitor, or a combination of a HER3 inhibitor and an EGFR inhibitor, wherein the patient has a tumor that has been characterized in that cells from the tumor express high levels of EGFR homodimer. 168. A method of determining whether a patient diagnosed with cancer is indicated as likely to be responsive to treatment with a FIER3 inhibitor, an EGFR inhibitor, or a combination of a FIER3 inhibitor and an EGFR inhibitor, comprising measuring the expression of at least one of AREG, TGF-a, and EGFR homodimer in a sample from the patient, wherein the sample comprises tumor cells, and high levels of one or more of AREG, TGF-a, and EGFR homodimer in the sample indicates that the patient is likely to be responsive to treatment with a FIER3 inhibitor, an EGFR inhibitor, or a combination of a FIER3 inhibitor and an EGFR inhibitor. 231. A method of treating a cancer, comprising administering to a patient diagnosed with said cancer a therapeutically effective amount of (i) a HER3 inhibitor, (ii) a combination of a HER3 iinhibitor and a B-Raf inhibitor, (iii) a combination of a HER3 inhibitor and a MEK inhibitor, or (iv) a combination of a HER3 inhibitor, a B-Raf inhibitor, and a MEK inhibitor, wherein the patient has a tumor that has been characterized in that cells from the tumor express a neuregulin. 303. A method of determining whether a patient diagnosed with cancer is indicated as likely to be responsive to treatment with (i) a HER3 inhibitor, (ii) a combination of a HER3 inhibitor and a B-Raf inhibitor, (iii) a combination of a HER3 inhibitor and a MEK inhibitor, or (iv) a combination of a HER3 inhibitor, a B-Raf inhibitor, and a MEK inhibitor, comprising measuring the expression of a neuregulin, wherein high levels of the neuregulin in the sample indicates that the patient is likely to be responsive to treatment with (i) a HER3 inhibitor, (ii) a combination of a HER3 inhibitor and a B-Raf inhibitor, (iii) a combination of a HER3 inhibitor and a MEK inhibitor, or (iv) a combination of a HER3 inhibitor, a B-Raf inhibitor, and a MEK inhibitor.
最新评论
暂无评论。